Limits...
Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).

Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Göke R, Márquez Rodriguez E, Nilsson PM, Pagkalos E, Penfornis A, Schaper NC, Wangnoo SK, Kothny W, Bader G - Int. J. Clin. Pract. (2013)

Bottom Line: The adjusted odds ratio was 1.96 (95% CI: 1.85, 2.07; p < 0.001).Safety events were reported infrequently and safety profiles of vildagliptin and other OADs were consistent with previous data.In addition, EDGE illustrates that conducting large-scale, prospective, real-life studies poses challenges but yields valuable clinical information complementary to RCTs.

View Article: PubMed Central - PubMed

Affiliation: I.G. - Endocrinologie, Campus Gasthuisberg, Leuven, Belgium.

Show MeSH

Related in: MedlinePlus

Time course of mean (± SEM) HbA1c over ≥ 52 weeks of observation of large cohorts of patients with T2DM receiving vildagliptin and another OAD (solid line, filled triangles) or dual OAD, non-DPP-4 inhibitor combination therapy (dashed line, open circles). The numbers of observations available in each cohort, for each time window are provided below the figure.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4231206&req=5

fig01: Time course of mean (± SEM) HbA1c over ≥ 52 weeks of observation of large cohorts of patients with T2DM receiving vildagliptin and another OAD (solid line, filled triangles) or dual OAD, non-DPP-4 inhibitor combination therapy (dashed line, open circles). The numbers of observations available in each cohort, for each time window are provided below the figure.

Mentions: Figure1 illustrates HbA1c time course in both cohorts, with final HbA1c changes at 12 months of −1.19% (95% CI: −1.21%, −1.18%) in vildagliptin-treated patients and −0.99% (95% CI: −1.01%, −0.97%) in comparator-treated patients (analysis not prespecified in protocol). Baseline body weight (mean ± SEM) was 81.4 ± 0.5 kg in the vildagliptin cohort and 77.9 ± 0.1 kg in the comparator cohort. The change from BL to end-point in body weight was −1.6 ± 0.03 kg with vildagliptin, and −0.3 ± 0.03 kg with comparator.


Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).

Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Göke R, Márquez Rodriguez E, Nilsson PM, Pagkalos E, Penfornis A, Schaper NC, Wangnoo SK, Kothny W, Bader G - Int. J. Clin. Pract. (2013)

Time course of mean (± SEM) HbA1c over ≥ 52 weeks of observation of large cohorts of patients with T2DM receiving vildagliptin and another OAD (solid line, filled triangles) or dual OAD, non-DPP-4 inhibitor combination therapy (dashed line, open circles). The numbers of observations available in each cohort, for each time window are provided below the figure.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4231206&req=5

fig01: Time course of mean (± SEM) HbA1c over ≥ 52 weeks of observation of large cohorts of patients with T2DM receiving vildagliptin and another OAD (solid line, filled triangles) or dual OAD, non-DPP-4 inhibitor combination therapy (dashed line, open circles). The numbers of observations available in each cohort, for each time window are provided below the figure.
Mentions: Figure1 illustrates HbA1c time course in both cohorts, with final HbA1c changes at 12 months of −1.19% (95% CI: −1.21%, −1.18%) in vildagliptin-treated patients and −0.99% (95% CI: −1.01%, −0.97%) in comparator-treated patients (analysis not prespecified in protocol). Baseline body weight (mean ± SEM) was 81.4 ± 0.5 kg in the vildagliptin cohort and 77.9 ± 0.1 kg in the comparator cohort. The change from BL to end-point in body weight was −1.6 ± 0.03 kg with vildagliptin, and −0.3 ± 0.03 kg with comparator.

Bottom Line: The adjusted odds ratio was 1.96 (95% CI: 1.85, 2.07; p < 0.001).Safety events were reported infrequently and safety profiles of vildagliptin and other OADs were consistent with previous data.In addition, EDGE illustrates that conducting large-scale, prospective, real-life studies poses challenges but yields valuable clinical information complementary to RCTs.

View Article: PubMed Central - PubMed

Affiliation: I.G. - Endocrinologie, Campus Gasthuisberg, Leuven, Belgium.

Show MeSH
Related in: MedlinePlus